The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

6276–6300 of 8593

  • SevereFDA (Drugs)·D-801-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mirtazapine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mirtazapine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mirtazapine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-723-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxyurea Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxyurea active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxyurea active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-508-2015·2015-04-29

    Alpha Chymotrypsin Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Alpha Chymotrypsin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Alpha Chymotrypsin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-937-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tramadol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tramadol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tramadol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-496-2015·2015-04-29

    Attix Pharmaceuticals Recalls DMSA Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-704-2015·2015-04-29

    Attix Pharmaceuticals Recalls Heptaminol Hydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Heptaminol Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Heptaminol Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-509-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amantadine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amantadine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amantadine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-587-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cinacalcet HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cinacalcet HCI active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Cinacalcet HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-849-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Acetate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to a risk of penicillin cross-contamination.

    Product
    Potassium Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-819-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitrofurantoin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitrofurantoin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Nitrofurantoin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-578-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorobutanol Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chlorobutanol Hemihydrate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorobutanol Hemihydrate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-822-2015·2015-04-29

    Attix Pharmaceuticals Recalls Olsalazine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Olsalazine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Olsalazine Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-875-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ranitidine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ranitidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ranitidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-729-2015·2015-04-29

    Attix Pharmaceuticals Recalls Idoxuridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Idoxuridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Idoxuridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-629-2015·2015-04-29

    Attix Pharmaceuticals Recalls Diclofenac Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Diclofenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Diclofenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-621-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-544-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bisacodyl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bisacodyl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bisacodyl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-675-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flibanserin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flibanserin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flibanserin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-879-2015·2015-04-29

    Ribavirin Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Ribavirin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ribavirin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-691-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formestane API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formestane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Formestane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-665-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etomidate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etomidate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etomidate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-803-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mitomycin C Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mitomycin C active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitomycin C active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-915-2015·2015-04-29

    Attix Pharmaceuticals Recalls Taurolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of taurolidine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Taurolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-548-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromhexine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Bromhexine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Bromhexine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide